STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the World Health Organization. This study analyzed factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the short regimen. The factors associated with FoR outcomes identified in this study should be considered when determining the optimal shortened treatment regimen.
Published: August 1, 2022
Sign up to receive our monthly Research Roundup email, which offers a selection of new public health research from major journals.
Recent Abstracts
Information About New Federal Regulations for Opioid Treatment Programs (OTPs)
Centering Country Ownership and Leadership: The Data for Health Initiative’s Approach
Mass Media Campaigns
Data for Health: Advancing Gender Equity
The Index of Tobacco Control Sustainability
Index of Tobacco Control Sustainability (ITCS): India Subnational Tobacco Control
Index of Tobacco Control Sustainability (ITCS): Indonesia Subnational Tobacco Control
Considerations for Planning Childhood Blood Lead Surveillance
Air Quality Monitoring Toolkit: Assessing Second-Hand Smoke in Hospitality Venues
Association between high-threshold practices and buprenorphine treatment termination